EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Birth in the Neonatal HBV Vaccination Era and Hepatitis B Surface Antigen Seroclearance in People With HIV-1 and HBV Coinfection on Tenofovir-containing Antiretroviral Therapy

Yu-Shan Huang iD, Hsin-Yun Sun iD, Kuan-Yin Lin iD, Sung-Hsi Huang iD, Yi-Chia Huang iD, Wang-Da Liu, Guan-Jhou Chen iD, Kai-Hsiang Chen, Li-Hsin Su, Yi-Ching Su, Wen-Chun Liu, Sui-Yuan Chang und 1 weitere

Clinical Infectious Diseases · 11.07.2026

DOI: 10.1093/cid/ciag429 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 11.07.2026. Verfasst von Yu-Shan Huang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Hauptthemen laut MEDLINE: Tenofovir, HIV Infections, Hepatitis B Surface Antigens, Coinfection. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The impact of long-term tenofovir-containing antiretroviral therapy (ART) on hepatitis B surface antigen (HBsAg) seroclearance in people with HIV-1 (PWH) and HBV coinfection remains under-defined, particularly in HBV-hyperendemic regions with universal neonatal vaccination programs.

Methods

HBsAg-positive PWH receiving tenofovir-containing ART between 2011 and 2023 were followed until December 2025. Demographics, HBV serologic markers, plasma HBV DNA, and liver fibrosis stage were collected. Cox proportional hazards models were used to identify factors associated with HBsAg seroclearance. Clinical and hepatic outcomes were compared with seroclearance status.

Results

After a median follow-up of 9.4 years, 35 (8.4%) of 415 PWH achieved HBsAg seroclearance during a total of 3600 person-years of tenofovir-containing ART, corresponding to an incidence rate of 0.97 per 100 person-years. Among them, 37.1% (13/35) tested positive for anti-HBs at the time of seroclearance. In multivariable analysis, birth in universal neonatal HBV vaccination era (after July 1986) (adjusted hazard ratio [aHR] 13.56, 95% confidence interval [CI] 6.08–30.28, P < .001), baseline HBsAg ≤250 IU/mL (aHR 7.36, 95% CI 3.29–16.50, P < .001), and higher baseline ALT level (aHR 1.00 per 1-U/L increase, 95% CI 1.00–1.01, P < .001) were independently associated with HBsAg seroclearance. None of PWH who achieved HBsAg seroclearance developed seroreversion, cirrhosis, or hepatocellular carcinoma (HCC), whereas 6.6% and 2.1% of PWH without seroclearance developed cirrhosis and HCC, respectively.

Conclusions

Despite long-term tenofovir-containing ART, HBsAg seroclearance was uncommon (0.97% annually) among PWH with HBV coinfection. Birth in the neonatal HBV vaccination era and lower baseline HBsAg level were 2 independent predictors of HBsAg seroclearance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TenofovirHIV InfectionsHepatitis B Surface AntigensCoinfectionHepatitis BHepatitis B VaccinesHumansFemaleAdultMaleHepatitis B virusHIV-1Infant, NewbornAnti-HIV AgentsMiddle AgedDNA, Viral

Stichwörter der Autor:innen

functional curehepatitis B virushuman immunodeficiency virusnucleos(t)ide analogtenofovir

Substanzen

TenofovirHepatitis B Surface AntigensHepatitis B VaccinesAnti-HIV AgentsDNA, Viral

Autor:innen und Institutionen

  • Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
  • Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan.
  • Department of Tropical Medicine and Parasitology, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Department of Medicine, National Taiwan University Cancer Center, Taipei, Taiwan.
  • Infection Control Room, Min-Sheng General Hospital, Taoyuan, Taiwan.
  • Department of Laboratory Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.

ORCID-Profile: Yu-Shan Huang, Hsin-Yun Sun, Kuan-Yin Lin, Sung-Hsi Huang, Yi-Chia Huang, Guan-Jhou Chen, Chien-Ching Hung

Zitieren

APA

Huang, Y. S., Sun, H. Y., Lin, K. Y., Huang, S. H., Huang, Y. C., Liu, W. D., Chen, G. J., Chen, K. H., Su, L. H., Su, Y. C., Liu, W. C., Chang, S. Y., & Hung, C. C. (2026). Birth in the Neonatal HBV Vaccination Era and Hepatitis B Surface Antigen Seroclearance in People With HIV-1 and HBV Coinfection on Tenofovir-containing Antiretroviral Therapy. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag429

Vancouver

Huang YS, Sun HY, Lin KY, Huang SH, Huang YC, Liu WD, et al. Birth in the Neonatal HBV Vaccination Era and Hepatitis B Surface Antigen Seroclearance in People With HIV-1 and HBV Coinfection on Tenofovir-containing Antiretroviral Therapy. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag429

BibTeX
@article{Huang2026,
  author = {Huang, Yu-Shan and Sun, Hsin-Yun and Lin, Kuan-Yin and Huang, Sung-Hsi and Huang, Yi-Chia and Liu, Wang-Da and Chen, Guan-Jhou and Chen, Kai-Hsiang and Su, Li-Hsin and Su, Yi-Ching and Liu, Wen-Chun and Chang, Sui-Yuan and Hung, Chien-Ching},
  title = {Birth in the Neonatal HBV Vaccination Era and Hepatitis B Surface Antigen Seroclearance in People With HIV-1 and HBV Coinfection on Tenofovir-containing Antiretroviral Therapy},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciag429}
}
Kostenlos starten →